| Literature DB >> 33271858 |
Sylwia Bajkacz1, Paulina Adamczewska1, Klaudia Kokoszka1, Elżbieta Kycia-Słocka1, Adam Sochacki2,3, Ewa Felis2.
Abstract
The increase in the production and consumption of pharmaceuticals increases their presence in the global environment, which may result in direct threats to living organisms. For this reason, there is a need for new methods to analyze drugs in environmental samples. Here, a new procedure for separating and determining selected drugs (diclofenac, ibuprofen, and carbamazepine) from bottom sediment and water samples was developed. Drugs were determined by ultra-high performance liquid chromatography coupled with an ultraviolet detector (UHPLC-UV). In this work, a universal and single-step sample treatment, based on supramolecular solvents (SUPRAS), was proposed to isolate selected anticonvulsants and nonsteroidal anti-inflammatory drugs (NSAIDs) from sediment samples. The following parameters were experimentally selected: composition of the supramolecular solvent (composition THF:H2O (v/v), amount of decanoic acid), volume of extractant, sample mass, extraction time, centrifugation time, and centrifugation speed. Finally, the developed procedure was validated. A Speedisk procedure was also developed to extract selected drugs from water samples. The recovery of analytes using the SUPRAS procedure was in the range of 88.8-115%, while the recoveries of the Speedisk solid-phase extraction procedure ranged from 81.0-106%. The effectiveness of the sorption of the tested drugs by sediment was also examined.Entities:
Keywords: Speedisk; liquid chromatography; micropollutants; supramolecular solvent-based microextraction
Mesh:
Substances:
Year: 2020 PMID: 33271858 PMCID: PMC7729498 DOI: 10.3390/molecules25235671
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chromatogram of analytes standard solution and internal standard.
Figure 2Effect of the THF:H2O volume ratio on analyte recovery.
Figure 3Effect of (A) volume of THF and (B) mass of decanoic acid per volume of supramolecular solvent.
Drug recovery after applying the developed SUPRAS procedure and Speedisk solid phase extraction procedure (n = 6).
| Compound | Concentration | Recovery (%) | RSD |
|---|---|---|---|
| SUPRAS procedure | |||
| CBZ | 1.25 | 115 | 7.2 |
| 10 | 96.3 | 4.1 | |
| 20 | 98.8 | 7.3 | |
| DIC | 1.25 | 97.0 | 8.2 |
| 10 | 88.5 | 3.5 | |
| 20 | 90.8 | 1.6 | |
| IBU | 1.25 | 112 | 2.8 |
| 10 | 103 | 0.3 | |
| 20 | 98.4 | 3.2 | |
| Speedisk solid phase extraction procedure | |||
| CBZ | 0.5 | 100 | 1.1 |
| 2 | 97.8 | 2.4 | |
| 4 | 97.3 | 0.6 | |
| DIC | 0.5 | 103 | 2.6 |
| 2 | 106 | 2.0 | |
| 4 | 103 | 1.8 | |
| IBU | 0.5 | 81.0 | 2.9 |
| 2 | 98.5 | 1.8 | |
| 4 | 102 | 5.6 | |
Figure 4Chromatograms of bottom sediment sample extracts: (A) without added standards (blank sample), (B) spiked with drugs obtained after SUPRAS microextraction.
Figure 5Chromatograms of water sample extracts: (A) blank sample, (B) samples of water spiked with drugs obtained after Speedisk solid-phase extraction.
Linear regression equations of calibration curves and calculated regression parameters (n = 6).
| Compound | Linear Range | Calibration Curve Equation | Sxy | Sa | Sb | R2 a | LOQ b | LOD c |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
|
| 0.5–25.0 µg g−1 | y = 0.4853x + 0.1092 | 0.4635 | 0.0204 | 0.2619 | 0.9912 | 1.25 µg g−1 | 0.42 µg g−1 |
|
| y = 0.1196x + 0.0517 | 0.0605 | 0.0027 | 0.0342 | 0.9975 | |||
|
| y = 0.0786x + 0.0849 | 0.0413 | 0.0018 | 0.0233 | 0.9973 | |||
|
| ||||||||
|
| 0.05–5.0 µg L−1 | y = 0.6159x − 0.0264 | 0.0191 | 0.0042 | 0.0118 | 0.9998 | 0.05 µg L−1 | 0.017 µg L−1 |
|
| y = 0.1571x − 0.0004 | 0.0132 | 0.0029 | 0.0081 | 0.9983 | |||
|
| y = 0.2503x + 0.0217 | 0.0317 | 0.0070 | 0.0196 | 0.9961 | |||
a R2—correlation coefficient.; b LOD—limit of detection.; c LOQ—limit of quantification.
Comparison of the developed SUPRAS microextraction method with other methods to extract drugs from sediment samples described in the literature.
| Method | Detection | Compound | LOD/LOQ | Linear Range | Recovery (%) | Volume of Extractant | Extraction/Analysis Time |
|
|---|---|---|---|---|---|---|---|---|
| PLE/SPE-LC | MS/MS | ibuprofen | LOD | 0.05–10 µg g−1 | 35–135 | 1 mL | 11 min + SPE/45 min | [ |
| SLE/SPE-UPLC | MS/MS | ibuprofen | - | – | 85–106.5 | 1 mL | 210 min + SPE/– | [ |
| PLE/SPE-HPLC | MS/MS | diclofenac | LOQ | – | – | 1 mL | 15 min + SPE/– | [ |
| PLE-HPLC | MS | ibuprofen | LOQ | 10–100 µg L−1 | 68–112 | 40 mL | 40 min/25–30 min | [ |
| USE-SPE-HPLC | DAD | ibuprofen | LOQ | – | 85.8–102 | 150 µL | 35.5 min + SPE/– | [ |
| PLE-SPE-LC | MS/MS | ibuprofen | - | – | 40–130 | 1 mL | 15–35 min + SPE/– | [ |
| USE-SPE-LC | MS/MS | ibuprofen | LOQ | 10 ng g−1–20 µg g−1 | 44–81 | 200 µL | 10 min + SPE/28 min | [ |
| PLE-SPE-LC | MS/MS | ibuprofen | MQL | 10 ng g−1–2 µg g−1 | 60–82 | 1 mL | 31 min + SPE/– | [ |
| SBSE-HF-LPME-LC | MS | ibuprofen | - | 0.5–8 mg L−1 | 57–62 | 10 µL | 20–22 h/– | [ |
| PLE-HF-LPME-LC | MS | ibuprofen | MLD | 3.9–4000 ng mL−1 | 101–109 | 25 µL | 176 min/26 min | [ |
| SUPRAS-UHPLC | UV | ibuprofen | LOD | 0.5–25 µg g−1 | 88.5–115 | 700 µL | 30 min/7 min | this work |
Comparison of the developed Speedisk solid phase extraction method with other methods to extract drugs from water samples described in the literature.
| Method | Detection | Compound | LOD/LOQ | Linear Range | Recovery (%) | Volume of Extractant | Extraction/Analysis Time | Ref. |
|---|---|---|---|---|---|---|---|---|
| SPE-GC | MS | ibuprofen | LOD: | 5–50 ng L−1 | 67–80 | 200 µL | SPE/62 min | [ |
| SPE-GC | MS | ibuprofen | LOQ: | – | 70–100 | 50 µL | SPE/38 min | [ |
| SPE-LC | MS | ibuprofen | – | – | 46–97 | 2 mL | SPE/40 min | [ |
| SPE-LC | MS/MS | ibuprofen | LOD: | – | 62–117 | – | – | [ |
| SPE-GC | MS | ibuprofen | LOQ: | 0.1–10 ng µL−1 | 77–93 | 100 µL | SPE/32 min | [ |
| SPE-GC | MS | ibuprofen | LOD: | 10–2000 ng L−1 | 67–76 | 100 µL | SPE/50.5 min | [ |
| SPE-HPLC | MS/MS | ibuprofen | LOD: | 1–250 µg L−1 | 56–77 | 300 µL | SPE/20–43 min | [ |
| SPE-GC | MS | ibuprofen | LOQ: | 10 ng g−1–2 µg g−1 | 50–99 | 0.5 mL | SPE/– | [ |
| SPE-GC | MS | ibuprofen | ILD: | 0.02–25 mg mL−1 | 84–157 | 130 µL | SPE/56 min | [ |
| SPE-GC | MS | ibuprofen | LOD: | 0.06–400 ng L−1 | 92–102 | 105 µL | SPE/– | [ |
| Speedisk-UHPLC | UV | ibuprofen | LOD: | 0.05–10 µg L−1 | 81–106 | 500 µL | 60 min/7 min | this work |
The gradient elution program and the mobile phase flow rate.
| Time (min) | Solvent A (%) a | Solvent B (%) a | Flow Rate (mL min−1) |
|---|---|---|---|
| 0.0 | 40 | 60 | 0.2 |
| 1.0 | 45 | 55 | 0.7 |
| 2.0 | 45 | 55 | 0.6 |
| 3.0 | 45 | 55 | 0.5 |
| 3.5 | 80 | 20 | 0.7 |
| 4.0 | 80 | 20 | 0.7 |
| 4.5 | 85 | 15 | 0.4 |
| 4.9 | 85 | 15 | 0.3 |
| 5.0 | 100 | 0 | 0.7 |
| 7.0 | 100 | 0 | 0.7 |
a Solvent A: acetonitrile, solvent B: 0.05% TFA in water.